Condition: Hepatocellular Carcinoma · Lenvatinib · PD-1 Inhibitor · Sponsor: Sun Yat-sen University
Hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and programmed cell death protein-1 (PD-1) inhibitor have shown promising results for advanced hepatocellular carcinoma (HCC). However, the evidence for infiltrative is limited. In this study, we aimed to describe the efficacy and safety of lenvatinib and PD-1 inhibitor with HAIC plus lenvatinib for infiltrative HCC.
This description comes directly from the study's public registry record.
Qunfang Zhou, MD · 86 19868000115 · zhouqun988509@163.com
Feng Duan, MD · 86 13910984586 · duanfeng@vip.sina.com
Always discuss trial participation with your own doctor first.
| Chinese PLA General hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06333561